These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32026389)

  • 1. Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis.
    Alcázar Navarrete B; Boucot I; Naya I; Tombs L; Lipson DA; Compton C; Sousa AR; Feldman G
    Pulm Ther; 2018 Dec; 4(2):171-183. PubMed ID: 32026389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
    Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
    J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
    Requena G; Czira A; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1431-1444. PubMed ID: 37465818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
    Driessen MT; Whalen J; Seewoodharry Buguth B; Vallejo-Aparicio LA; Naya IP; Asukai Y; Alcázar-Navarrete B; Miravitlles M; García-Río F; Risebrough NA
    Respir Res; 2018 Nov; 19(1):224. PubMed ID: 30458866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
    Maleki-Yazdi MR; Singh D; Anzueto A; Tombs L; Fahy WA; Naya I
    Adv Ther; 2017 Jan; 33(12):2188-2199. PubMed ID: 27796912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
    Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
    Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
    Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C; O'Dell D; Galkin D; Newlands A; Fahy WA
    Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
    J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
    [No Abstract]   [Full Text] [Related]  

  • 15. Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease.
    Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; MacKnight SD; Hahn B
    Pulm Ther; 2021 Jun; 7(1):203-219. PubMed ID: 33728597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
    Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β
    Weng CF; Wu CC; Wu MH; Lin FJ
    Chest; 2023 Apr; 163(4):799-814. PubMed ID: 36442662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
    Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
    Sethi S; Clark B; Bengtson LGS; Buysman EK; Palli S; Sargent A; Shaikh A; Ferguson GT
    Int J Chron Obstruct Pulmon Dis; 2023; 18():625-641. PubMed ID: 37155497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
    Miravitlles M; Urrutia G; Mathioudakis AG; Ancochea J
    Respir Res; 2017 Nov; 18(1):196. PubMed ID: 29178871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.